Israel's Intec Pharma, a long-term study of long-term use of tablets for the treatment of Parkinson's disease, expects 2019 to start earning money from the program.
Intec has recently completed the registration of 462 patients in a Phase III study on a tablet that opens as an accordion; levodopa medications remain in the stomach for 8-12 hours and require a lower daily dose. The results are expected mid-2019.
A Phase II study found that the "day out time" dropped by 45 percent, which gave patients more than two additional hours of movement per day.
"I feel very comfortable that we have an acceptable program here. I would like to see as much effect as possible, but commercial viability is due to any effect size," said Jeffrey Meckler, executive director of Intec. After the news conference on Wednesday.
"I hope that next year we will be able to profit from the value gained from the Parkinson program, whether it is the sale of the company, the sale of the program or the licensing partnership," said M. Mekler, who took over in July 2017.
He said that a large proportion of Parkinson's companies were interested in the program, but he refused to work out.
Assuming a market share of 10%, Meckler said: "We have a drug worth more than $ 300 million a year."
It is possible that the hall will compete with Amneal Pharmaceuticals "Rytary", which also reduces extraneous time.
Intec also looks at the delivery of tablets for the treatment of cannabis and has begun trials at an early stage.
"The Cannabino program has far greater potential than Parkinson's patients," Meckler said, adding that the company decided to provide medical cannabis before the Phase III studies.
The strategy of Intec is to look for existing medicines and place them on the delivery platform where the medications are folded into film with layers that opens up as an accordion.
Intec is trying to adapt its platform to detecting drugs from Novartis and is expected to decide on its viability in early 2019, Meckler said.
The Nasdaq listed company has raised $ 35 million in the second quarter, helping to fund the Parkinson's study. Although not yet profitable, Intec at the end of June was $ 66 million in cash and tens of a quarter.
"We do not even make more money before Parkinson's data" next year, Meckler said.